Variable name;level;Overall;IVM;At least one COS;p;test
;n;266;175;84;;
Age;[0 -30);63 (23.7);45 (25.7);16 (19.0);0.185;
;[30 -35);121 (45.5);83 (47.4);35 (41.7);;
;[35 -40);78 (29.3);44 (25.1);32 (38.1);;
;40+;4 (1.5);3 (1.7);1 (1.2);;
Age (mean);;32.8 (3.7);32.4 (3.8);33.5 (3.7);0.042;
Number of children;0;181 (68.0);120 (68.6);56 (66.7);0.921;
;1;53 (19.9);35 (20.0);17 (20.2);;
;More than 1;32 (12.0);20 (11.4);11 (13.1);;
BMI;<18.5;16 (6.2);5 (2.9);10 (12.0);0.026;
;18.5-24.9;185 (71.2);121 (71.2);58 (69.9);;
;25-29.9;47 (18.1);35 (20.6);12 (14.5);;
;>=30;12 (4.6);9 (5.3);3 (3.6);;
BMI (mean);;22.0 [20.3, 24.4];22.5 [20.3, 25.1];21.5 [20.1, 24.3];0.074;nonnorm
Treatment center;Curie Paris;171 (64.3);115 (65.7);53 (63.1);0.784;
;Curie St Cloud;95 (35.7);60 (34.3);31 (36.9);;
Genetic analysis;No;56 (21.1);34 (19.4);21 (25.0);0.388;
;Yes;210 (78.9);141 (80.6);63 (75.0);;
Hereditary predisposition;No;159 (76.8);109 (79.0);46 (73.0);0.451;
;Yes;48 (23.2);29 (21.0);17 (27.0);;
Inflammatory BC;No;264 (99.2);173 (98.9);84 (100.0);0.822;
;Yes;2 (0.8);2 (1.1);0 (0.0);;
Clinical Tumor size (mm);;31.7 (20.1);36.7 (21.1);21.7 (13.9);<0.001;
Clinical T stage (TNM);T0-T1;101 (38.1);42 (24.0);56 (67.5);<0.001;
;T2;135 (50.9);109 (62.3);22 (26.5);;
;T3-T4;29 (10.9);24 (13.7);5 (6.0);;
Clinical N stage (TNM);N0;169 (63.8);101 (57.7);62 (74.7);0.012;
;N1-N2-N3;96 (36.2);74 (42.3);21 (25.3);;
SBR grade;Grade I;11 (4.2);8 (4.6);3 (3.6);0.772;
;Grade II;97 (36.6);63 (36.2);34 (40.5);;
;Grade III;157 (59.2);103 (59.2);47 (56.0);;
BC subtype;Luminal;121 (50.4);75 (47.2);45 (59.2);0.388;
;TNBC;55 (22.9);37 (23.3);14 (18.4);;
;HER2+/HR+;50 (20.8);37 (23.3);13 (17.1);;
;HER2+/HR-;14 (5.8);10 (6.3);4 (5.3);;
Histological type;NST;252 (94.7);169 (96.6);77 (91.7);0.230;
;Lobular;6 (2.3);3 (1.7);3 (3.6);;
;Others;8 (3.0);3 (1.7);4 (4.8);;
Neoajuvant chemotherapy;No;120 (45.1);39 (22.3);78 (92.9);<0.001;
;Yes;146 (54.9);136 (77.7);6 (7.1);;
Chemotherapy setting;Adjuvant;120 (45.1);39 (22.3);78 (92.9);<0.001;
;NAC;146 (54.9);136 (77.7);6 (7.1);;
Fertility preservation discussion;No;3 (1.1);2 (1.1);1 (1.2);1.000;
;Yes;263 (98.9);173 (98.9);83 (98.8);;
